{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:44:43Z","timestamp":1776876283211,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Australian Research Council's Discovery Projects funding scheme","award":["120102778"],"award-info":[{"award-number":["120102778"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1RO1CA155061-1"],"award-info":[{"award-number":["1RO1CA155061-1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11095-016-1949-6","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T18:14:48Z","timestamp":1464200088000},"page":"2107-2116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation"],"prefix":"10.1007","volume":"33","author":[{"given":"Hideyuki","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Yakushiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Prud\u2019homme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Onoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,25]]},"reference":[{"issue":"3","key":"1949_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jps.2600790307","volume":"79","author":"S Venkataram","year":"1990","unstructured":"Venkataram S, Awni WM, Jordan K, Rahman YE. Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. J Pharm Sci. 1990;79(3):216\u20139.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1949_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/jop.1994.10.553","volume":"10","author":"H Sajjadi","year":"1994","unstructured":"Sajjadi H, Soheilian M, Ahmadieh H, Hassanein K, Parvin M, Azarmina M, et al. Low dose cyclosporin-A therapy in Behcet\u2019s disease. J Ocul Pharmacol. 1994;10(3):553\u201360.","journal-title":"J Ocul Pharmacol"},{"issue":"6767","key":"1949_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/bmj.302.6767.4","volume":"302","author":"AW Thomson","year":"1991","unstructured":"Thomson AW, Neild GH. Cyclosporin: use outside transplantation. BMJ. 1991;302(6767):4\u20135.","journal-title":"BMJ"},{"issue":"1","key":"1949_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/icvts\/ivu081","volume":"19","author":"Y Matsuda","year":"2014","unstructured":"Matsuda Y, Chen F, Miyata H, Date H. Once-daily oral administration of cyclosporine in a lung transplant patient with a history of renal toxicity of calcineurin inhibitors. Interact Cardiovasc Thorac Surg. 2014;19(1):171\u20133.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"5","key":"1949_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1164\/ajrccm.161.5.9903102","volume":"161","author":"J Bousquet","year":"2000","unstructured":"Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720\u201345.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1949_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2013.03.026","volume":"448","author":"H Sato","year":"2013","unstructured":"Sato H, Ogawa K, Kojo Y, Kawabata Y, Mizumoto T, Yamada S, et al. Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy. Int J Pharm. 2013;448(1):282\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"1949_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jconrel.2009.04.014","volume":"138","author":"S Onoue","year":"2009","unstructured":"Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release. 2009;138(1):16\u201323.","journal-title":"J Control Release"},{"issue":"1","key":"1949_CR8","doi-asserted-by":"publisher","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","volume":"293","author":"NA Bobadilla","year":"2007","unstructured":"Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol. 2007;293(1):F2\u20139.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1949_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.proghi.2004.04.001","volume":"39","author":"R Rezzani","year":"2004","unstructured":"Rezzani R. Cyclosporine A, and adverse effects on organs: histochemical studies. Prog Histochem Cytochem. 2004;39(2):85\u2013128.","journal-title":"Prog Histochem Cytochem"},{"issue":"4","key":"1949_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.2042-7158.1991.tb06688.x","volume":"43","author":"G Ismailos","year":"1991","unstructured":"Ismailos G, Reppas C, Dressman JB, Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol. 1991;43(4):287\u20139.","journal-title":"J Pharm Pharmacol"},{"issue":"4\u20135","key":"1949_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i45.40","volume":"19","author":"HM Courrier","year":"2002","unstructured":"Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002;19(4\u20135):425\u201398.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"4","key":"1949_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/bdd.2510150406","volume":"15","author":"SB Charnick","year":"1994","unstructured":"Charnick SB, Yu Z, Athill LV, Karara AH, Tse FL, Lau DT. Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat. Biopharm Drug Dispos. 1994;15(4):317\u201327.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"1949_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/jps.22299","volume":"100","author":"S Onoue","year":"2011","unstructured":"Onoue S, Aoki Y, Kawabata Y, Matsui T, Yamamoto K, Sato H, et al. Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases. J Pharm Sci. 2011;100(2):622\u201333.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1949_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa043204","volume":"354","author":"AT Iacono","year":"2006","unstructured":"Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354(2):141\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"1949_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/jamp.2008.0714","volume":"22","author":"J Behr","year":"2009","unstructured":"Behr J, Zimmermann G, Baumgartner R, Leuchte H, Neurohr C, Brand P, et al. Munich lung transplant G. lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv. 2009;22(2):121\u201330.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"3","key":"1949_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/jam.1991.4.151","volume":"4","author":"GK Crompton","year":"1991","unstructured":"Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991;4(3):151\u20136.","journal-title":"J Aerosol Med"},{"issue":"1","key":"1949_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1517\/17425247.1.1.67","volume":"1","author":"HW Frijlink","year":"2004","unstructured":"Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1(1):67\u201386.","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"1949_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2125.1980.tb01078.x","volume":"9","author":"SW Clarke","year":"1980","unstructured":"Clarke SW, Pavia D. Lung mucus production and mucociliary clearance: methods of assessment. Br J Clin Pharmacol. 1980;9(6):537\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1949_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1165\/ajrcmb\/1.2.145","volume":"1","author":"BE Lehnert","year":"1989","unstructured":"Lehnert BE, Valdez YE, Tietjen GL. Alveolar macrophage-particle relationships during lung clearance. Am J Respir Cell Mol Biol. 1989;1(2):145\u201354.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"1949_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1517\/17425240903089310","volume":"6","author":"S Onoue","year":"2009","unstructured":"Onoue S, Misaka S, Kawabata Y, Yamada S. New treatments for chronic obstructive pulmonary disease and viable formulation\/device options for inhalation therapy. Expert Opin Drug Deliv. 2009;6(8):793\u2013811.","journal-title":"Expert Opin Drug Deliv"},{"key":"1949_CR21","first-page":"1269","volume":"8","author":"X Wu","year":"2013","unstructured":"Wu X, Zhang W, Hayes Jr D, Mansour HM. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int J Nanomedicine. 2013;8:1269\u201383.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"1949_CR22","doi-asserted-by":"publisher","first-page":"E190","DOI":"10.1208\/aapsj0902021","volume":"9","author":"GS Zijlstra","year":"2007","unstructured":"Zijlstra GS, Rijkeboer M, Jan van Drooge D, Sutter M, Jiskoot W, van de Weert M, et al. Characterization of a cyclosporine solid dispersion for inhalation. AAPS J. 2007;9(2):E190\u20139.","journal-title":"AAPS J"},{"issue":"4","key":"1949_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11095-010-0332-2","volume":"28","author":"PC Kwok","year":"2011","unstructured":"Kwok PC, Tunsirikongkon A, Glover W, Chan HK. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm Res. 2011;28(4):788\u201396.","journal-title":"Pharm Res"},{"issue":"1","key":"1949_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.08.010","volume":"420","author":"K Yamasaki","year":"2011","unstructured":"Yamasaki K, Kwok PC, Fukushige K, Prud\u2019homme RK, Chan HK. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm. 2011;420(1):34\u201342.","journal-title":"Int J Pharm"},{"issue":"3\u20134","key":"1949_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ejps.2009.04.002","volume":"37","author":"S Misaka","year":"2009","unstructured":"Misaka S, Sato H, Yamauchi Y, Onoue S, Yamada S. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: physicochemical characterization and biomarker profiling in rats. Eur J Pharm Sci. 2009;37(3\u20134):469\u201376.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1949_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.peptides.2009.09.032","volume":"31","author":"S Misaka","year":"2010","unstructured":"Misaka S, Aoki Y, Karaki S, Kuwahara A, Mizumoto T, Onoue S, et al. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides. 2010;31(1):72\u20138.","journal-title":"Peptides"},{"issue":"6","key":"1949_CR27","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/jps.23102","volume":"101","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Kojo Y, Yamada S, Onoue S. Respirable dry powder formulation of bleomycin for developing a pulmonary fibrosis animal model. J Pharm Sci. 2012;101(6):2074\u201381.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1949_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.addr.2011.04.005","volume":"63","author":"SM D\u2019Addio","year":"2011","unstructured":"D\u2019Addio SM, Prud\u2019homme RK. Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. 2011;63(6):417\u201326.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"1949_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/adhm.201400766","volume":"4","author":"NM Pinkerton","year":"2015","unstructured":"Pinkerton NM, Gindy ME, Calero-Ddel CV, Wolfson T, Pagels RF, Adler D, et al. Single-step assembly of multimodal imaging nanocarriers: MRI and long-wavelength fluorescence imaging. Adv Healthcare Mater. 2015;4(9):1376\u201385.","journal-title":"Adv Healthcare Mater"},{"issue":"1","key":"1949_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1021\/la702902b","volume":"24","author":"ME Gindy","year":"2008","unstructured":"Gindy ME, Panagiotopoulos AZ, Prud\u2019homme RK. Composite block copolymer stabilized nanoparticles: simultaneous encapsulation of organic actives and inorganic nanostructures. Langmuir. 2008;24(1):83\u201390.","journal-title":"Langmuir"},{"key":"1949_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40199-014-0087-0","volume":"23","author":"B Gajra","year":"2015","unstructured":"Gajra B, Dalwadi C, Patel R. Formulation and optimization of itraconazole polymeric lipid hybrid nanoparticles (Lipomer) using box behnken design. Daru. 2015;23:3.","journal-title":"Daru"},{"issue":"1","key":"1949_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67\u201374.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1949_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jps.2600750502","volume":"75","author":"PR Byron","year":"1986","unstructured":"Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75(5):433\u20138.","journal-title":"J Pharm Sci"},{"issue":"8","key":"1949_CR34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/17425247.5.8.909","volume":"5","author":"HK Chan","year":"2008","unstructured":"Chan HK. What is the role of particle morphology in pharmaceutical powder aerosols? Expert Opin Drug Deliv. 2008;5(8):909\u201314.","journal-title":"Expert Opin Drug Deliv"},{"issue":"8789","key":"1949_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/0140-6736(92)91646-P","volume":"339","author":"AG Alexander","year":"1992","unstructured":"Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 1992;339(8789):324\u20138.","journal-title":"Lancet"},{"issue":"1","key":"1949_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1089\/jamp.2009.0748","volume":"23","author":"S Groves","year":"2010","unstructured":"Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, et al. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv. 2010;23(1):31\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"1949_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2500\/108854101778249230","volume":"22","author":"MS Dykewicz","year":"2001","unstructured":"Dykewicz MS. Newer and alternative non-steroidal treatments for asthmatic inflammation. Allergy Asthma Proc. 2001;22(1):11\u20135.","journal-title":"Allergy Asthma Proc"},{"issue":"2\u20133","key":"1949_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0014-2999(01)00975-X","volume":"420","author":"SL Underwood","year":"2001","unstructured":"Underwood SL, McMillan S, Reeves R, Hunt J, Brealey CJ, Webber S, et al. Effects of cyclosporin A administered into the airways against antigen-induced airway inflammation and hyperreactivity in the rat. Eur J Pharmacol. 2001;420(2\u20133):165\u201373.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1949_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1165\/ajrcmb.12.3.7873190","volume":"12","author":"G Brusselle","year":"1995","unstructured":"Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol. 1995;12(3):254\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"1949_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1124\/pr.56.4.2","volume":"56","author":"PJ Barnes","year":"2004","unstructured":"Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56(4):515\u201348.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"1949_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3109\/15412555.2010.528086","volume":"7","author":"C O\u2019Donnell","year":"2010","unstructured":"O\u2019Donnell C, Newbold P, White P, Thong B, Stone H, Stockley RA. 3-Chlorotyrosine in sputum of COPD patients: relationship with airway inflammation. COPD. 2010;7(6):411\u20137.","journal-title":"COPD"},{"issue":"5","key":"1949_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1513\/pats.200601-006AW","volume":"3","author":"DS Postma","year":"2006","unstructured":"Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(5):434\u20139.","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"1949_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.etap.2013.08.015","volume":"37","author":"DK Ingawale","year":"2014","unstructured":"Ingawale DK, Mandlik SK, Naik SR. Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s): a critical discussion. Environ Toxicol Pharmacol. 2014;37(1):118\u201333.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"2","key":"1949_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.healun.2010.08.024","volume":"30","author":"EF Nash","year":"2011","unstructured":"Nash EF, Stephenson A, Helm EJ, Durie PR, Tullis E, Singer LG, et al. Impact of lung transplantation on serum lipids in adults with cystic fibrosis. J Heart Lung Transplant. 2011;30(2):188\u201393.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"1949_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00210-014-1074-1","volume":"388","author":"HM El-Gowelli","year":"2015","unstructured":"El-Gowelli HM, El-Mas MM. Central modulation of cyclosporine-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(3):351\u201361.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"1949_CR46","first-page":"437","volume":"48","author":"M Bohdanecka","year":"1999","unstructured":"Bohdanecka M, Schuck O, Chadimova M, Sedivy J, Glagolicova A, Skibova J, et al. Nephrotoxicity of cyclosporin A in hereditary hypertriglyceridemic rats. Physiol Res. 1999;48(6):437\u201343.","journal-title":"Physiol Res"},{"issue":"5","key":"1949_CR47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","volume":"12","author":"H Podder","year":"2001","unstructured":"Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC, et al. Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations. J Am Soc Nephrol. 2001;12(5):1059\u201371.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1949_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/00075198-200112000-00003","volume":"7","author":"AJ Olyaei","year":"2001","unstructured":"Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care. 2001;7(6):384\u20139.","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"1949_CR49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481\u2013508.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1949_CR50","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/009127000004001106","volume":"40","author":"S Rohatagi","year":"2000","unstructured":"Rohatagi S, Calic F, Harding N, Ozoux ML, Bouriot JP, Kirkesseli S, et al. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J Clin Pharmacol. 2000;40(11):1211\u201326.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1949_CR51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1183\/09031936.04.00058504","volume":"23","author":"AT Iacono","year":"2004","unstructured":"Iacono AT, Corcoran TE, Griffith BP, Grgurich WF, Smith DA, Zeevi A, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004;23(3):384\u201390.","journal-title":"Eur Respir J"},{"issue":"3","key":"1949_CR52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/jamp.2013.1042","volume":"27","author":"TE Corcoran","year":"2014","unstructured":"Corcoran TE, Niven R, Verret W, Dilly S, Johnson BA. Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. J Aerosol Med Pulm Drug Deliv. 2014;27(3):178\u201384.","journal-title":"J Aerosol Med Pulm Drug Deliv"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-1949-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-016-1949-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-1949-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-016-1949-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T16:35:56Z","timestamp":1692376556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-016-1949-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,25]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["1949"],"URL":"https:\/\/doi.org\/10.1007\/s11095-016-1949-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,25]]},"assertion":[{"value":"4 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}